Skip to main navigation
Skip to content

Infinity Pharmaceuticals, Inc

Search
  • Toggle search form
  • Follow us on Twitter
  • Connect with us on LinkedIn

Investor Relations

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board
  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients
  • For Patients
  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Executive Leadership
      • Board of Directors
      • Committees
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
    • Analyst Coverage
    • Online Investor Kit
    • Information Request
  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
  • Contact Us

Press Releases

Q3 2022 Infinity Pharmaceuticals, Inc. Earnings Conference Call
Nov 14, 2022 at 8:30 AM EST
Listen to webcast

Keyword Search

  • Summary ToggleInfinity Pharmaceuticals Reports Full Year 2022 Financial Results
    March 28, 2023 at 4:05 PM EDT
  • Summary ToggleMEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
    February 23, 2023 at 7:00 AM EST
  • Summary ToggleInfinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
    November 22, 2022 at 8:35 AM EST
  • Summary ToggleInfinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
    November 14, 2022 at 7:07 AM EST
  • Summary ToggleInfinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
    November 14, 2022 at 7:05 AM EST
  • Summary ToggleInfinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
    November 7, 2022 at 8:25 AM EST
  • Summary ToggleInfinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
    August 31, 2022 at 7:00 AM EDT
  • Summary ToggleInfinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
    August 9, 2022 at 4:05 PM EDT
  • Summary ToggleInfinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
    August 2, 2022 at 8:25 AM EDT
  • Summary ToggleInfinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
    May 17, 2022 at 8:35 AM EDT

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

Shareholder Tools

  • RSS Feeds

    RSS Feeds

  • Email Alerts

    Email Alerts

  • Print

    Print

  • Email

    Email

Infinity Pharmaceuticals, Inc.

1100 Massachusetts Ave
Cambridge, MA 02138
617-453-1000

Terms and Conditions

  • Terms & Conditions
  • Privacy Policy
  • Forward Looking Statements
Connect With Us
  • Twitter
  • LinkedIn

Our Team

  • Our Team
    • Mission Values
    • Leadership Team
    • Board of Directors
    • Clinical Advisory Board
    • Scientific Advisory Board

Our Development Program

  • Our Development Program
    • Our Pipeline
    • Eganelisib
    • PI3K-Gamma
    • Selected Publications
    • Expanded Access
    • For Patients

Investor / Media

  • Investors/Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Online Investor Kit
    • Information Request

Join Us

  • Join Us
    • Our Community
    • Life at Infinity
    • Careers
    • Benefits
© 2023 Infinity Pharmaceuticals, Inc. All Rights Reserved.